Gastroenterology exam questions
3 exam-length papers covering every published domain for Gastroenterology.
DHA GES51713 papers · 510 Qs
What is riding on this exam
~AED 1,030
Exam fee, per attempt
Published by DHA. Paid again on every re-sit.
3
Attempts - in total
The cap is three across all UAE authorities, not three each.
60%
Pass mark
Pass or fail only. Your score is never released.
One failed attempt costs you the fee again, plus months of delay on your licence, your visa and your start date. This bank costs about a 4th of one exam fee.
Try two questions from this bank
Real questions from the bank - pick an answer to see the rationale and reference.
Q1Patient Safety, Professionalism, Ethics and Evidence-Based Practice
During a screening colonoscopy a caecal perforation occurs and is closed with clips; the patient is admitted for observation and recovers well. The endoscopist's approach to the patient afterwards should be to:
Choose an answer to see the rationale.
Q2Viral Hepatitis, Acute Liver Injury and Transplantation
A patient develops liver injury 5 weeks after starting a new drug. ALT is 8 times the upper limit of normal and ALP is 1.2 times the upper limit of normal. Which pattern does this represent and what is the corresponding R value?
Choose an answer to see the rationale.
Not sure where you stand? Sit 25 of these questions free, timed at real exam pace, and see which domains you are weakest in.
Take the free mock exam →Liked those? The full bank has 510 questions at this standard - every one with a rationale and a reference.
Get the full bank - AED 289What's inside
- ✓3 full-length papers (~150 Q each)
- ✓510 questions, no overlap between papers
- ✓Four options, one unambiguous best answer
- ✓A full rationale on every question
- ✓A real guideline or textbook reference
- ✓Every sub-topic in the published blueprint
Exam route by authority
| Authority | Delivered by | Specialist title |
|---|---|---|
| DHA - Dubai | Prometric | Computer-based MCQ |
| DOH - Abu Dhabi | Pearson VUE | Computer-based MCQ |
| MOHAP - Northern Emirates | Prometric | Computer-based MCQ |
| SCFHS - Saudi Arabia | Prometric / Pearson | Computer-based MCQ |
| QCHP - Qatar | Prometric | Computer-based MCQ |
| NHRA - Bahrain | Prometric | Computer-based MCQ |
| OMSB - Oman | Prometric | MCQ then oral viva |
Assessment mode depends on your licence title as well as your profession. Confirm your own route on your Sheryan / TAMM eligibility notice.
What the Gastroenterology exam covers
The published blueprint for this exam breaks into 13 domains and 255 testable sub-topics. Our bank covers every one of them - here is the full map, so you can see exactly what you are expected to know.
Oesophageal Diseases~8% (part of the SCFHS/DHA published section 'Oesophageal and Gastric Diseases' at 14%; split here for granularity - est.)19 topics
- GERD: pathophysiology, Montreal definition, extra-oesophageal and atypical presentations
- PPI therapy: dosing, on-demand vs maintenance, PPI-refractory reflux, long-term safety concerns
- Ambulatory pH and pH-impedance monitoring: on vs off therapy, DeMeester score, symptom association probability
- High-resolution manometry and the Chicago Classification v4.0
- Achalasia subtypes I-III: diagnosis, timed barium oesophagram, pneumatic dilatation vs Heller myotomy vs POEM
- Other motility disorders: distal oesophageal spasm, hypercontractile (jackhammer) oesophagus, absent contractility, EGJ outflow obstruction
- +13 more in the bank
Gastric and Duodenal Diseases and Helicobacter pylori~6% (remainder of the SCFHS/DHA 'Oesophageal and Gastric Diseases' 14% section - est. split)19 topics
- Peptic ulcer disease: pathogenesis, H. pylori vs NSAID vs idiopathic ulcers
- Helicobacter pylori: invasive and non-invasive testing, effect of PPI/antibiotics on test accuracy
- H. pylori eradication regimens: bismuth quadruple, concomitant, levofloxacin salvage, clarithromycin resistance and regional resistance patterns
- Confirmation of eradication and management of repeated treatment failure, culture and susceptibility testing
- NSAID and aspirin gastropathy: risk stratification, co-therapy, COX-2 selectivity, resumption after bleeding
- Refractory and recurrent ulcers: gastrinoma, Crohn's, malignancy, non-adherence
- +13 more in the bank
Gastrointestinal Bleeding~15% (SCFHS/DHA published section: 15%)20 topics
- Initial resuscitation in acute GI bleed: airway, fluids, restrictive vs liberal transfusion thresholds (Hb 7 g/dL)
- Risk scores: Glasgow-Blatchford, Rockall, AIMS65, Oakland score for lower GI bleeding, and outpatient management criteria
- Pre-endoscopic pharmacotherapy: PPI infusion vs high-dose oral, prokinetics, tranexamic acid evidence (HALT-IT)
- Timing of upper endoscopy (within 24 hours) and evidence against very early (<12 h) endoscopy in high-risk patients
- Forrest classification of peptic ulcer stigmata and rebleeding risk by class
- Endoscopic haemostasis techniques: injection, thermal contact, argon plasma coagulation, through-the-scope and over-the-scope clips, haemostatic powders/gels
- +14 more in the bank
Pancreatic Diseases~8% (part of the SCFHS/DHA published section 'Pancreaticobiliary Diseases' at 15%; split here for granularity - est.)20 topics
- Acute pancreatitis: revised Atlanta classification, diagnostic triad, aetiological work-up including idiopathic cases
- Severity prediction: BISAP, APACHE II, persistent organ failure; early aggressive vs moderate fluid resuscitation (WATERFALL)
- Early management: goal-directed lactated Ringer's, early enteral feeding, analgesia, role and non-role of antibiotics
- Gallstone pancreatitis: timing of ERCP (only for cholangitis/obstruction) and index-admission cholecystectomy
- Local complications: acute peripancreatic fluid collection, pseudocyst, acute necrotic collection, walled-off necrosis
- Infected necrosis: diagnosis, step-up approach, percutaneous vs EUS-guided drainage with lumen-apposing metal stents, endoscopic necrosectomy
- +14 more in the bank
Biliary Tract and Gallbladder Disease~7% (remainder of the SCFHS/DHA 'Pancreaticobiliary Diseases' 15% section - est. split)19 topics
- Gallstone disease: risk factors, biliary colic, natural history of asymptomatic stones
- Acute cholecystitis: Tokyo Guidelines grading, cholecystectomy timing, percutaneous vs EUS-guided gallbladder drainage
- Choledocholithiasis: ASGE/ESGE probability stratification, MRCP vs EUS vs ERCP selection
- Acute cholangitis: Charcot/Reynolds, Tokyo Guidelines severity, timing of urgent biliary decompression, antibiotics
- ERCP technique and accessories: cannulation strategies, sphincterotomy, sphincteroplasty (large balloon dilation), mechanical/cholangioscopic lithotripsy
- Difficult stones and altered anatomy: Roux-en-Y and Billroth II, balloon enteroscopy-assisted ERCP, EUS-directed transgastric ERCP (EDGE)
- +13 more in the bank
Chronic Liver Disease, Cirrhosis and Portal Hypertension~13% (part of the SCFHS/DHA published section 'Liver and Liver Related Conditions and Diseases' at 25%; split here for granularity - est.)20 topics
- Non-invasive fibrosis assessment: FIB-4, NFS, transient elastography (FibroScan), ELF, MR elastography and their cut-offs
- Compensated advanced chronic liver disease and the Baveno VII criteria, clinically significant portal hypertension and HVPG >=10 mmHg
- MASLD/MASH (formerly NAFLD/NASH): nomenclature, metabolic criteria, natural history, resmetirom and GLP-1 based therapy, weight loss targets
- Alcohol-related liver disease: quantification, alcohol-associated hepatitis, Maddrey DF, MELD, Lille score, corticosteroid use, abstinence and relapse prevention
- Ascites: SAAG interpretation, diagnostic paracentesis, sodium restriction, diuretic regimens, refractory ascites, large-volume paracentesis with albumin
- Spontaneous bacterial peritonitis: diagnosis (PMN >=250), treatment, albumin indications, primary and secondary prophylaxis, resistance patterns
- +14 more in the bank
Inflammatory Bowel Disease~4% (part of the SCFHS/DHA published section 'Inflammatory Bowel Diseases, Small and Large Intestine' at 6%; SCFHS Fellowship promotion blueprint weights IBD at 25% - est. split for the licensure paper)20 topics
- Epidemiology, genetics (NOD2/CARD15) and environmental risk factors; distinguishing UC from Crohn's disease
- Diagnostic work-up: ileocolonoscopy with segmental biopsies, faecal calprotectin, CT/MR enterography, intestinal ultrasound
- Disease classification: Montreal classification, Mayo endoscopic subscore, SES-CD, UCEIS
- Ulcerative colitis medical management: 5-ASA optimisation, topical therapy, steroids, thiopurines
- Crohn's disease medical management by phenotype: inflammatory, stricturing, penetrating; exclusive enteral nutrition
- Anti-TNF therapy: infliximab, adalimumab, certolizumab - loss of response, immunogenicity, combination therapy
- +14 more in the bank
Small and Large Intestine Disorders (non-IBD)~3% (remainder of the SCFHS/DHA 'Inflammatory Bowel Diseases, Small and Large Intestine' 6% section - est. split)20 topics
- Coeliac disease: serology (tTG-IgA with total IgA), Marsh classification, HLA-DQ2/DQ8, gluten challenge, non-responsive and refractory coeliac disease
- Non-coeliac gluten sensitivity and wheat allergy
- Small intestinal bacterial overgrowth: breath testing limitations, aspirate culture, antibiotic cycling
- Chronic diarrhoea: osmotic vs secretory vs inflammatory vs fatty; stool osmotic gap, faecal fat, faecal elastase
- Bile acid diarrhoea: SeHCAT, 7alpha-C4, sequestrant therapy
- Microscopic colitis: lymphocytic vs collagenous, drug associations, budesonide
- +14 more in the bank
Gastrointestinal and Hepatobiliary Malignancies~9% (SCFHS/DHA published section 'Gastrointestinal Malignancies': 9%)20 topics
- Oesophageal adenocarcinoma and squamous cell carcinoma: risk factors, staging with EUS/PET-CT, endoscopic vs surgical vs multimodal therapy
- Gastric adenocarcinoma: Lauren classification, H. pylori attribution, early gastric cancer and endoscopic resection criteria
- Hereditary diffuse gastric cancer (CDH1) and prophylactic gastrectomy
- Gastric MALT lymphoma: H. pylori eradication as first-line therapy, t(11;18) non-responders, follow-up
- Gastrointestinal stromal tumours: EUS features, risk stratification, KIT/PDGFRA mutations, imatinib
- Subepithelial lesions: EUS layer of origin, leiomyoma, lipoma, pancreatic rest, carcinoid; sampling strategies
- +14 more in the bank
GI Motility, Functional GI Disorders and Nutrition~6% (SCFHS/DHA published section 'Gastroenterology Nutrition Motility Disorders': 6%)19 topics
- Rome IV framework for disorders of gut-brain interaction and the biopsychosocial model
- Irritable bowel syndrome subtypes: diagnostic criteria, alarm features, limited testing strategy
- IBS therapy: low-FODMAP diet, fibre, antispasmodics, rifaximin, eluxadoline, linaclotide, lubiprostone, neuromodulators, gut-directed hypnotherapy and CBT
- Chronic constipation: normal transit, slow transit, defaecatory disorder; transit studies and anorectal manometry with balloon expulsion
- Pharmacological therapy for constipation: osmotic and stimulant laxatives, secretagogues, prucalopride, naloxegol for opioid-induced constipation
- Biofeedback and pelvic floor rehabilitation for dyssynergic defaecation
- +13 more in the bank
Endoscopy Practice, Sedation and Procedural Complications (Miscellaneous)~4% (est. - the DHA exam coverage list includes a 'Miscellaneous' heading and names Cotton & Williams Practical Gastrointestinal Endoscopy as a core reference; not a separately weighted SCFHS section)19 topics
- Informed consent for endoscopy: material risks, alternatives, capacity, and documentation standards
- Pre-procedure risk assessment: ASA grade, airway assessment, anticoagulation and antiplatelet management per ASGE/ESGE/BSG guidance
- Sedation for endoscopy: midazolam/opioid, propofol, monitored anaesthesia care, capnography, reversal agents and rescue
- Management of sedation-related adverse events: hypoxaemia, aspiration, hypotension, arrhythmia
- Bowel preparation regimens, split dosing, preparation in renal impairment and constipation; consequences of inadequate preparation
- Antibiotic prophylaxis in endoscopy: where it is and is not indicated (cirrhosis with GI bleed, PEG, EUS-FNA of cysts, ERCP with incomplete drainage)
- +13 more in the bank
Patient Safety, Professionalism, Ethics and Evidence-Based Practice~10% (SCFHS/DHA published: Patient Safety 5% + Professionalism and Ethics 5%; the SCFHS Fellowship blueprint instead embeds these across domains)20 topics
- Principles of medical ethics: autonomy, beneficence, non-maleficence, justice, applied to endoscopic and hepatology decisions
- Informed consent, assent, capacity assessment and surrogate decision-making
- Truth-telling, breaking bad news (SPIKES) and family-mediated disclosure norms in Gulf practice
- Confidentiality, data protection, and the limits of disclosure to family and employers
- Disclosure of medical error and open disclosure after a procedural complication
- Do-not-resuscitate decisions, futility, palliative care and end-of-life care in end-stage liver disease
- +14 more in the bank
Before you book your exam
Gastroenterology licensing in the GCC
Requirements, timelines and salary by country
Do I need to sit a Prometric exam?
Check the format and pass mark for your authority
Am I eligible to apply?
Free eligibility check against the PQR criteria
Licensing in the UAE
DHA, DOH and MOHAP compared
Exam preparation support
One-to-one guidance alongside the question banks
Guides and articles
Dataflow, PCC, exam booking and relocation
Frequently asked questions
No. Every item is original, written by our team against the exam blueprint published by the health authorities. Real, recalled or leaked exam content breaches the testing bodies' rules and can lead to a permanent exam ban - we do not sell it, and neither should anyone else.
Still unsure whether you even need this exam?
Your route depends on your profession, your licence title and the authority. We have guided over 1,000 professionals through GCC licensing - tell us your situation and we will confirm exactly what you need to sit.